In vitro and in vivo efficacy of edelfosine-loaded lipid nanoparticles against glioma

Journal of Controlled Release

Volumn 156, Issue 3, 2011, Pages 421-426

  Estella Hermoso De Mendoza, Ander ^a   Préat, Veronique ^b   Mollinedo, Faustino ^c   Blanco Prieto, María J ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^c UNIVERSITY OF SALAMANCA   (Spain)

Author keywords

Edelfosine; Glioma; Lipid nanoparticles

Indexed keywords

ANTI-TUMOR ACTIVITIES; ANTI-TUMOR AGENTS; ANTICANCER DRUG; ANTIPROLIFERATIVE EFFECT; BRAIN TISSUE; BRAIN TUMORS; EDELFOSINE; GLIOMA; GLIOMA CELL LINES; GLIOMA CELLS; IN-VITRO; IN-VIVO; LIPID NANOPARTICLES; MOUSE MODELS; NUDE MICE; ORAL ADMINISTRATION; P-GLYCOPROTEIN; TUMOR GROWTH;

ASSAYS; BRAIN; CELL CULTURE; CELLS; DRUG INTERACTIONS; DRUG PRODUCTS; GLYCOPROTEINS; MAMMALS; NANOPARTICLES;

TUMORS;

EDELFOSINE; GLYCEROL BEHENATE; GLYCEROL PALMITOSTEARATE; GLYCOPROTEIN P; POLYSORBATE 80;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BRAIN TISSUE; CANCER INHIBITION; CELL VIABILITY; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; GLIOMA; GLIOMA CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SINGLE DRUG DOSE; TUMOR GROWTH; TUMOR XENOGRAFT;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; BRAIN; BRAIN NEOPLASMS; CELL LINE, TUMOR; GLIOMA; HUMANS; LIPIDS; MICE; MICE, INBRED BALB C; MICE, NUDE; NANOPARTICLES; PHOSPHOLIPID ETHERS; POLYSORBATES;

EID: 82755182780     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2011.07.030     Document Type: Article

References (33)

1. W.M. Pardridge Blood-brain barrier delivery Drug Discov. Today 12 1-2 2007 54 61 (Pubitemid 46014479)
2. N.J. Abbott, A.A. Patabendige, D.E. Dolman, S.R. Yusof, and D.J. Begley Structure and function of the blood-brain barrier Neurobiol. Dis. 37 1 2010 13 25
3. A.M. Palmer The blood-brain barrier Neurobiol. Dis. 37 1 2010 1 2
4. P. Blasi, S. Giovagnoli, A. Schoubben, M. Ricci, and C. Rossi Solid lipid nanoparticles for targeted brain drug delivery Adv. Drug Deliv. Rev. 59 6 2007 454 477 (Pubitemid 47259226)
5. W.M. Pardridge Brain drug development and brain drug targeting Pharm. Res. 24 9 2007 1729 1732 (Pubitemid 47206626)
6. W.M. Pardridge Drug targeting to the brain Pharm. Res. 24 9 2007 1733 1744 (Pubitemid 47206623)
7. W.M. Pardridge Blood-brain barrier delivery of protein and non-viral gene therapeutics with molecular Trojan horses J. Control. Release 122 3 2007 345 348 (Pubitemid 47404662)
8. S. Gururangan, and H.S. Friedman Innovations in design and delivery of chemotherapy for brain tumors Neuroimaging Clin. N. Am. 12 4 2002 583 597 (Pubitemid 36015493)
9. W. Loscher, and H. Potschka Blood-brain barrier active efflux transporters: ATP-binding cassette gene family NeuroRx 2 1 2005 86 98 (Pubitemid 40128029)
10. P. Kleihues, and W. Cavanee P. Kleihues, W. Cavanee, WHO Classification of Tumors. Pathology and Genetics 2000 IARC press Lyon
11. H. Bolhuis, H.W. van Veen, B. Poolman, A.J. Driessen, and W.N. Konings Mechanisms of multidrug transporters FEMS Microbiol. Rev. 21 1 1997 55 84 (Pubitemid 27376759)
12. L. Cerveny, P. Pavek, J. Malakova, F. Staud, and Z. Fendrich Lack of interactions between breast cancer resistance protein (bcrp/abcg2) and selected antiepileptic agents Epilepsia 47 3 2006 461 468 (Pubitemid 43351546)
13. M. Maliepaard, M.A. van Gastelen, A. Tohgo, F.H. Hausheer, R.C. van Waardenburg, L.A. de Jong, D. Pluim, J.H. Beijnen, and J.H. Schellens Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918 Clin. Cancer Res. 7 4 2001 935 941 (Pubitemid 32708732)
14. A. Beduneau, F. Hindre, A. Clavreul, J.C. Leroux, P. Saulnier, and J.P. Benoit Brain targeting using novel lipid nanovectors J. Control. Release 126 1 2008 44 49 (Pubitemid 351175685)
15. M.F. Bennewitz, and W.M. Saltzman Nanotechnology for delivery of drugs to the brain for epilepsy Neurotherapeutics 6 2 2009 323 336
16. M.L. Bondi, E.F. Craparo, G. Giammona, and F. Drago Brain-targeted solid lipid nanoparticles containing riluzole: preparation, characterization and biodistribution Nanomedicine (Lond.) 5 1 2010 25 32
17. A. Estella-Hermoso de Mendoza, M.A. Campanero, J. de la Iglesia-Vicente, C. Gajate, F. Mollinedo, and M.J. Blanco-Prieto Antitumor alkyl ether lipid edelfosine: tissue distribution and pharmacokinetic behavior in healthy and tumor-bearing immunosuppressed mice Clin. Cancer Res. 15 3 2009 858 864
18. A. Estella-Hermoso de Mendoza, B. Lasa-Saracibar, M.A. Campanero, and M. Blanco-Prieto H.S. Naiwa, Lipid Nanoparticles in Biomedicine Encyclopedia of Nanoscience and Nanotechnology 15 2010 455 478
19. P.P. Constantinides, and K.M. Wasan Lipid formulation strategies for enhancing intestinal transport and absorption of P-glycoprotein (P-gp) substrate drugs: in vitro/in vivo case studies J. Pharm. Sci. 96 2 2007 235 248 (Pubitemid 46363554)
20. B.D. Rege, J.P. Kao, and J.E. Polli Effects of nonionic surfactants on membrane transporters in Caco-2 cell monolayers Eur. J. Pharm. Sci. 16 4-5 2002 237 246
21. A. Estella-Hermoso de Mendoza, M.A. Campanero, F. Mollinedo, and M.J. Blanco-Príeto Comparative study of A HPLC-MS assay versus an UHPLC-MS/MS for anti-tumoral alkyl lysophospholipid edelfosine determination in both biological samples and in lipid nanoparticulate systems J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 877 2009 4035 4041
22. A. Garrigues, J. Nugier, S. Orlowski, and E. Ezan A high-throughput screening microplate test for the interaction of drugs with P-glycoprotein Anal. Biochem. 305 1 2002 106 114 (Pubitemid 34575830)
23. T. Mosmann Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays J. Immunol. Methods 65 1-2 1983 55 63 (Pubitemid 14203433)
24. C. Olbrich, and R.H. Muller Enzymatic degradation of SLN-effect of surfactant and surfactant mixtures Int. J. Pharm. 180 1 1999 31 39 (Pubitemid 29131440)
25. M.V. Varma, Y. Ashokraj, C.S. Dey, and R. Panchagnula P-glycoprotein inhibitors and their screening: a perspective from bioavailability enhancement Pharmacol. Res. 48 4 2003 347 359 (Pubitemid 36945333)
26. P.K. Dudeja, K.M. Anderson, J.S. Harris, L. Buckingham, and J.S. Coon Reversal of multidrug resistance phenotype by surfactants: relationship to membrane lipid fluidity Arch. Biochem. Biophys. 319 1 1995 309 315
27. E.D. Hugger, B.L. Novak, P.S. Burton, K.L. Audus, and R.T. Borchardt A comparison of commonly used polyethoxylated pharmaceutical excipients on their ability to inhibit P-glycoprotein activity in vitro J. Pharm. Sci. 91 9 2002 1991 2002 (Pubitemid 36254935)
28. Y. Chen, G. Dalwadi, and H.A. Benson Drug delivery across the blood-brain barrier Curr. Drug Deliv. 1 4 2004 361 376
29. T.M. Goppert, and R.H. Muller Polysorbate-stabilized solid lipid nanoparticles as colloidal carriers for intravenous targeting of drugs to the brain: comparison of plasma protein adsorption patterns J. Drug Target. 13 3 2005 179 187 (Pubitemid 40668171)
30. J. Kreuter Nanoparticulate systems for brain delivery of drugs Adv. Drug Deliv. Rev. 47 1 2001 65 81 (Pubitemid 32209233)
31. W.J. van Blitterswijk, and M. Verheij Anticancer alkylphospholipids: mechanisms of action, cellular sensitivity and resistance, and clinical prospects Curr. Pharm. Des. 14 21 2008 2061 2074
32. C. Gajate, and F. Mollinedo Biological activities, mechanisms of action and biomedical prospect of the antitumor ether phospholipid ET-18-OCH3 (edelfosine), a proapoptotic agent in tumor cells Curr. Drug Metab. 3 5 2002 491 525 (Pubitemid 34987482)
33. G.B. Henderson, and B.P. Strauss Evidence for cAMP and cholate extrusion in C6 rat glioma cells by a common anion efflux pump J. Biol. Chem. 266 3 1991 1641 1645 (Pubitemid 21908349)